Predictive testing predicts high risks for cancer in healthy individuals in the context of a strong family history. With the advent of targeted cancer treatments there has been a move of the initial genetic test into mainstream oncology. With new approaches increasing the efficiency and reducing the...
Next-generation sequencing technologies have ushered in the capability to assess multiple genes in parallel for genetic alterations that may contribute to inherited risk for cancers in families. Thus, gene panel testing is now an option in the setting of genetic counseling and testing for cancer risk...
Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial.doi:10.1093/jnci/dju379... Ranjit,Manchanda,Kelly,... - 《Journal of the National Cancer Institute》 被引量: 60发表: 2015年 Persistent Underutilization of BRCA1/2 Te...
Genetic testing, to identify pathogenic or likely pathogenic variants in prostate cancer, is valuable in guiding treatment decisions for men with prostate cancer and to inform cancer prevention and early detection options for their immediate blood relatives. There are various guidelines and consensus stat...
* Gene names are typically abbreviated for ease of use because full names are often several words long. Usually, the cancer drugs and genetic tests listed in the table above have been developed concurrently; thus, the tests are referred to as “companion diagnostics.” These are laboratory tests...
Strategies to enhance identification of hereditary breast cancer gene carriers. Expert Rev Mol Diagn. 2020;20(9):861-865. doi:10.1080/14737159.2020.1816829PubMedGoogle ScholarCrossref 19. Lin J, Sharaf RN, Saganty R, et al. Achieving universal genetic assessment for women with...
von Hippel-Lindau (VHL) disease is a hereditary cancer syndrome caused by germline mutations in the VHL gene. Patients have significant morbidity and mortality secondary to vascular tumors. Disease management is centered on tumor surveillance that allows
Breast cancer in women at high risk: the role of rapid genetic testing for BRCA1 and -2 mutations and the consequences for treatment strategies. Specific clinical questions rise when patients, who are diagnosed with breast cancer, are at risk of carrying a mutation in BRCA1 and -2 gene due...
Aggressive breast cancers portend a poor prognosis, but current polygenic risk scores (PRSs) for breast cancer do not reliably predict aggressive cancers. Aggressiveness can be effectively recapitulated using tumor gene expression profiling. Thus, we sought to develop a PRS for the risk of recurrence...
The search for biomarkers in the management of lung cancer involves the use of multiple platforms to examine changes in gene, protein, and microRNA expression. Multiple studies have been published in an attempt to describe early detection, diagnostic, prognostic, and predictive biomarkers using chiefl...